-
Mar.062023NEWS
HanAll Biopharma’s Licensed Partner in China Announces Positive Topline Phase 3 Results for Batoclimab in Myasthenia Gravis
HanAll Biopharma’s Licensed Partner in China Announces Positive Topline Phase 3 Results for Batoclim..
-
Feb.022023NEWS
HanAll Biopharma Invests in Interon to Seek Collaboration Opportunities
HanAll Biopharma Invests in Interon to Seek Collaboration Opportunities
-
Feb.012023NEWS
HanAll Biopharma Reports Full-Year 2022 Results and Provides Business Update
HanAll Biopharma Reports Full-Year 2022 Results and Provides Business Update
-
Nov.162022NEWS
HanAll Biopharma Reports Third Quarter 2022 Results and Provides Business Update
HanAll Biopharma Reports Third Quarter 2022 Results and Provides Business Update
-
Oct.112022NEWS
HanAll’s Licensed Partner in China Enters Sublicense Agreement with CSPC to Further Accelerate Development of Batoclimab
HanAll’s Licensed Partner in China Enters Sublicense Agreement with CSPC to Further Accelerate Devel..
-
Oct.112022NOTICE
HanAll Biopharma’s Licensed Partner in China Provides Updates on Phase 3 Trial in Dry Eye Disease in China
HanAll Biopharma’s Licensed Partner in China Provides Updates on Phase 3 Trial in Dry Eye Disease in..